Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Exploris 480
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Colon
SUBMITTER: lu liu
LAB HEAD: lu liu
PROVIDER: PXD030121 | Pride | 2022-08-12
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
WD114LQB1.zip | Other | |||
WD114LQB1_UCinfG1.raw | Raw | |||
WD114LQB1_UCinfG2.raw | Raw | |||
WD114LQB1_UCinfG3.raw | Raw | |||
WD114LQB1_UCinfL1.raw | Raw |
Items per page: 5 1 - 5 of 13 |
Liu Lu L Pu Dan D Wang Dandan D Zhang Muhan M Zhou Chuan C Zhang Zhe Z Feng Baisui B
Frontiers in pharmacology 20220613
<b>Background:</b> Infliximab (IFX) is a potent therapeutic agent used for the treatment of conventional refractory ulcerative colitis (UC). However, the high non-response rate of IFX brings difficulties to clinical applications. In the context of proteomics research, our study of differentially expressed proteins (DEPs) is essential for non-response to IFX in UC patients and provides powerful insights into underlying drug resistance mechanisms. <b>Methods:</b> A total of 12 UC patients were div ...[more]